Skip to main content
Springer Nature Link
Account
Fig. 7: Correction of BCLX splicing from anti-apoptotic Bcl-xL to Bcl-xS sensitizes GBM cells to IR. | Cell Death & Disease

Fig. 7: Correction of BCLX splicing from anti-apoptotic Bcl-xL to Bcl-xS sensitizes GBM cells to IR.

From: Modification of BCLX pre-mRNA splicing has antitumor efficacy alone or in combination with radiotherapy in human glioblastoma cells

Fig. 7: Correction of BCLX splicing from anti-apoptotic Bcl-xL to Bcl-xS sensitizes GBM cells to IR.

A Schematic illustration of experiment design and treatment plan. B, C EdU assay demonstrated that Bclx-vMO could sensitize A172 cells to X-ray irradiation. Typical photos of the EdU assay were captured with confocal microscopy. D Colony formation assays using A172 cells with inhibition of Bcl-xL or control combined with or without IR treatment. E, F Apoptosis of A172 cells with BCLX splicing correction or control combined with or without IR were evaluated by flow cytometry. G The cell viability of 3D spheroid cultures of A172 cells was determined using Cell Titer-Glo 3D according to the instructions. H, I The dead cells in 3D spheroid cultures of A172 with BCLX splicing correction or control combined with or without IR were measured using SYTOX Green. J Western blot was performed to measure the levels of proteins related to apoptosis and autophagy in A172 cells with splicing modulation upon IR. K Kaplan–Meier survival analysis of GBM patients who received radiation based on Bcl-xL expression (TCGA datasets). Data are shown as mean values ± S.D. from ≥three independent experiments. One-way ANOVA followed by Dunnett’s multiple comparisons test are reported. For all panels “***” indicates p < 0.001, “****” indicates p < 0.0001.

Back to article page